Covered recipient · General Payments record
CHRISTINE THAI
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$298.93
19 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $298.93 | 19 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $69.05 | 5 |
| Amgen Inc. | $61.68 | 3 |
| Novartis Pharmaceuticals Corporation | $35.35 | 2 |
| AbbVie Inc. | $33.00 | 2 |
| GlaxoSmithKline, LLC. | $30.63 | 2 |
| Organon LLC | $30.08 | 3 |
| E.R. Squibb & Sons, L.L.C. | $23.17 | 1 |
| AstraZeneca Pharmaceuticals LP | $15.97 | 1 |
Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHRISTINE THAI
NPI 1043224587 · CMS profile ID 1470
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
HUNTINGTON BEACH, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1043224587?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
19 matching records · $298.93 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–19 of 19.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $14.85 | 12/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788962533 | CMS |
| Novartis Pharmaceuticals Corporation | $19.45 | 12/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813310637 | CMS |
| Organon LLC | $13.04 | 12/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837178759 | CMS |
| GlaxoSmithKline, LLC. | $13.90 | 11/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802010545 | CMS |
| Organon LLC | $5.31 | 11/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837178775 | CMS |
| Janssen Biotech, Inc. | $17.08 | 11/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788962535 | CMS |
| AbbVie Inc. | $21.57 | 10/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796147023 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.97 | 10/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829625629 | CMS |
| E.R. Squibb & Sons, L.L.C. | $23.17 | 08/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783527893 | CMS |
| Novartis Pharmaceuticals Corporation | $15.90 | 08/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813310633 | CMS |
| Organon LLC | $11.73 | 08/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837178767 | CMS |
| Amgen Inc. | $20.43 | 06/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825221083 | CMS |
| Janssen Biotech, Inc. | $13.21 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788962531 | CMS |
| Janssen Biotech, Inc. | $11.36 | 05/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788962529 | CMS |
| AbbVie Inc. | $11.43 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796147021 | CMS |
| Amgen Inc. | $19.46 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825221091 | CMS |
| Janssen Biotech, Inc. | $12.55 | 03/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788962537 | CMS |
| Amgen Inc. | $21.79 | 03/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825221087 | CMS |
| GlaxoSmithKline, LLC. | $16.73 | 01/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802522047 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,372,053.89 | 61 |
| PY2024 | Recipient | $8,444.46 | 4 |
| PY2024 | Principal investigator | $1,430,507.12 | 79 |
| PY2023 | Recipient | $8,498.49 | 1 |
| PY2023 | Principal investigator | $1,858,436.22 | 86 |
| PY2022 | Recipient | $72,841.00 | 2 |
| PY2022 | Principal investigator | $1,860,641.35 | 160 |
| PY2021 | Recipient | $2,012.04 | 2 |
| PY2021 | Principal investigator | $577,779.35 | 91 |
| PY2020 | Recipient | $2,580.07 | 2 |
| PY2020 | Principal investigator | $908,629.40 | 110 |
| PY2019 | Recipient | $16,824.73 | 4 |
| PY2019 | Principal investigator | $518,505.93 | 90 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
93 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $808.40 | 12/28/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792488435 |
| Recipient | Eli Lilly and Company | $16.15 | 12/17/2021 | Covered Recipient Physician | A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 819443765 |
| Principal investigator 1 | Eli Lilly and Company | $1,007.09 | 12/16/2021 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, TWO-ARM, PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 819461571 |
| Principal investigator 1 | ABBVIE INC. | $680.00 | 12/15/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | No dispute reported | 06/30/2026 | 792487141 |
| Principal investigator 1 | ABBVIE INC. | $19,589.70 | 12/07/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) | No dispute reported | 06/30/2026 | 792485743 |
| Principal investigator 1 | ABBVIE INC. | $2,669.65 | 12/02/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792485133 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/02/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792485275 |
| Principal investigator 1 | Eli Lilly and Company | $15,000.00 | 11/22/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 819453211 |
| Principal investigator 1 | ABBVIE INC. | $12,789.40 | 11/18/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) | No dispute reported | 06/30/2026 | 792483637 |
| Principal investigator 1 | ABBVIE INC. | $4,663.84 | 11/18/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792483821 |
| Principal investigator 1 | ABBVIE INC. | $416.00 | 11/17/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) | No dispute reported | 06/30/2026 | 792482867 |
| Principal investigator 1 | ABBVIE INC. | $157.95 | 11/17/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis | No dispute reported | 06/30/2026 | 792483359 |
| Principal investigator 1 | ABBVIE INC. | $2,082.00 | 11/17/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | No dispute reported | 06/30/2026 | 792483463 |
| Principal investigator 1 | ABBVIE INC. | $8,048.05 | 11/10/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792482523 |
| Principal investigator 1 | ABBVIE INC. | $3,181.30 | 11/04/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792481305 |
| Principal investigator 1 | ABBVIE INC. | $10,000.00 | 11/03/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment | No dispute reported | 06/30/2026 | 792480925 |
| Principal investigator 1 | Eli Lilly and Company | $561.92 | 10/26/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 819460511 |
| Principal investigator 1 | ABBVIE INC. | $2,653.80 | 10/14/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792479629 |
| Principal investigator 1 | ABBVIE INC. | $4,393.00 | 10/14/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis | No dispute reported | 06/30/2026 | 792479719 |
| Principal investigator 1 | ABBVIE INC. | $4,823.92 | 10/14/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | No dispute reported | 06/30/2026 | 792479833 |
| Recipient | Eli Lilly and Company | $1,995.89 | 10/08/2021 | Covered Recipient Physician | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 819443663 |
| Principal investigator 1 | ABBVIE INC. | $11,468.68 | 10/06/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792477631 |
| Principal investigator 1 | ABBVIE INC. | $1,896.72 | 10/06/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792477633 |
| Principal investigator 1 | ABBVIE INC. | $1,739.26 | 10/06/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 | No dispute reported | 06/30/2026 | 792477885 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 09/14/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) | No dispute reported | 06/30/2026 | 792475439 |
| Principal investigator 1 | ABBVIE INC. | $11,736.90 | 09/09/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 792475133 |
| Principal investigator 1 | ABBVIE INC. | $8,775.70 | 09/09/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792475201 |
| Principal investigator 1 | ABBVIE INC. | $630.25 | 09/09/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis | No dispute reported | 06/30/2026 | 792475295 |
| Principal investigator 1 | ABBVIE INC. | $6,155.54 | 09/01/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792473755 |
| Principal investigator 1 | ABBVIE INC. | $1,896.72 | 08/30/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792473179 |
| Principal investigator 1 | ABBVIE INC. | $48.27 | 08/18/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792472313 |
| Principal investigator 1 | ABBVIE INC. | $12,403.80 | 08/13/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792472131 |
| Principal investigator 1 | ABBVIE INC. | $2,080.00 | 07/29/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) | No dispute reported | 06/30/2026 | 792468989 |
| Principal investigator 1 | ABBVIE INC. | $9,500.00 | 07/29/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) | No dispute reported | 06/30/2026 | 792469177 |
| Principal investigator 1 | ABBVIE INC. | $5,426.70 | 07/29/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792470243 |
| Principal investigator 1 | ABBVIE INC. | $8,462.40 | 07/29/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792470245 |
| Principal investigator 1 | ABBVIE INC. | $6,295.10 | 07/29/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792470601 |
| Principal investigator 1 | ABBVIE INC. | $4,323.44 | 07/29/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | No dispute reported | 06/30/2026 | 792470959 |
| Principal investigator 1 | ABBVIE INC. | $3,646.72 | 07/29/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 | No dispute reported | 06/30/2026 | 792471245 |
| Principal investigator 1 | ABBVIE INC. | $1,625.30 | 07/14/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 792467623 |
| Principal investigator 1 | ABBVIE INC. | $205.63 | 07/12/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792467393 |
| Principal investigator 1 | ABBVIE INC. | $2,141.44 | 06/30/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) | No dispute reported | 06/30/2026 | 792464515 |
| Principal investigator 1 | ABBVIE INC. | $7,534.75 | 06/30/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792465237 |
| Principal investigator 1 | ABBVIE INC. | $1,321.65 | 06/30/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792465587 |
| Principal investigator 1 | ABBVIE INC. | $1,427.92 | 06/30/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | No dispute reported | 06/30/2026 | 792465901 |
| Principal investigator 1 | ABBVIE INC. | $2,755.58 | 06/30/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 | No dispute reported | 06/30/2026 | 792466209 |
| Principal investigator 1 | ABBVIE INC. | $2,682.88 | 06/08/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) | No dispute reported | 06/30/2026 | 792462417 |
| Principal investigator 1 | ABBVIE INC. | $1,683.92 | 06/08/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | No dispute reported | 06/30/2026 | 792462731 |
| Principal investigator 1 | ABBVIE INC. | $7,971.15 | 06/02/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792461663 |
| Principal investigator 1 | ABBVIE INC. | $3,246.10 | 05/27/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792460845 |
| Principal investigator 1 | ABBVIE INC. | $1,983.74 | 05/27/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 | No dispute reported | 06/30/2026 | 792461209 |
| Principal investigator 1 | ABBVIE INC. | $12,403.80 | 05/20/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792458799 |
| Principal investigator 1 | ABBVIE INC. | $1,289.20 | 05/05/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 792453879 |
| Principal investigator 1 | ABBVIE INC. | $1,683.92 | 05/03/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | No dispute reported | 06/30/2026 | 792453229 |
| Principal investigator 1 | ABBVIE INC. | $7,119.95 | 04/30/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792452503 |
| Principal investigator 1 | ABBVIE INC. | $16,728.57 | 04/29/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792450083 |
| Principal investigator 1 | ABBVIE INC. | $5,982.00 | 04/29/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792450089 |
| Principal investigator 1 | ABBVIE INC. | $11,500.00 | 04/22/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 792446711 |
| Principal investigator 1 | Eli Lilly and Company | $32,366.00 | 04/19/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | No dispute reported | 06/30/2026 | 819463661 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 04/13/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 | No dispute reported | 06/30/2026 | 792444937 |
| Principal investigator 1 | ABBVIE INC. | $10,748.18 | 04/02/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792442109 |
| Principal investigator 1 | ABBVIE INC. | $4,878.96 | 04/01/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | No dispute reported | 06/30/2026 | 792441727 |
| Principal investigator 1 | Eli Lilly and Company | $33,495.00 | 04/01/2021 | Non-covered Recipient Entity ACCURATE CLINICAL RESEARCH INC | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 819450177 |
| Principal investigator 1 | ABBVIE INC. | $2,125.82 | 03/31/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) | No dispute reported | 06/30/2026 | 792439673 |
| Principal investigator 1 | ABBVIE INC. | $4,085.28 | 03/30/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792437951 |
| Principal investigator 1 | ABBVIE INC. | $10,665.40 | 03/30/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792438519 |
| Principal investigator 1 | ABBVIE INC. | $1,682.94 | 03/30/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 | No dispute reported | 06/30/2026 | 792439533 |
| Principal investigator 1 | Eli Lilly and Company | $4,472.85 | 03/25/2021 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | No dispute reported | 06/30/2026 | 819457877 |
| Principal investigator 1 | ABBVIE INC. | $5,400.00 | 03/18/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 792434069 |
| Principal investigator 1 | ABBVIE INC. | $8,625.00 | 03/18/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 792434077 |
| Principal investigator 1 | Eli Lilly and Company | $518.65 | 03/08/2021 | Non-covered Recipient Entity HOAG MEMORIAL HOSPITAL PRESBYTERIAN | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 819457881 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 03/04/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) | No dispute reported | 06/30/2026 | 792431897 |
| Principal investigator 1 | ABBVIE INC. | $186.00 | 03/04/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792431979 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 03/04/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 | No dispute reported | 06/30/2026 | 792432081 |
| Principal investigator 1 | ABBVIE INC. | $1,625.30 | 03/03/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 792431707 |
| Principal investigator 1 | ABBVIE INC. | $2,956.54 | 03/02/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) | No dispute reported | 06/30/2026 | 792426687 |
| Principal investigator 1 | ABBVIE INC. | $10,679.35 | 03/02/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792429611 |
| Principal investigator 1 | ABBVIE INC. | $1,896.72 | 03/02/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792429617 |
| Principal investigator 1 | ABBVIE INC. | $6,809.45 | 03/02/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792430291 |
| Principal investigator 1 | ABBVIE INC. | $2,500.86 | 03/02/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 | No dispute reported | 06/30/2026 | 792431287 |
| Principal investigator 1 | ABBVIE INC. | $18,124.74 | 02/12/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period | No dispute reported | 06/30/2026 | 792423153 |
| Principal investigator 1 | ABBVIE INC. | $4,779.00 | 02/12/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792423171 |
| Principal investigator 1 | ABBVIE INC. | $5,325.82 | 01/28/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) | No dispute reported | 06/30/2026 | 792413065 |
| Principal investigator 1 | ABBVIE INC. | $5,854.72 | 01/28/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) | No dispute reported | 06/30/2026 | 792415887 |
| Principal investigator 1 | ABBVIE INC. | $8,256.33 | 01/28/2021 | Non-covered Recipient Entity MERIDIAN INVESTIGATOR NETWORK LLC | A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy | No dispute reported | 06/30/2026 | 792416773 |
| Principal investigator 1 | ABBVIE INC. | $2,307.68 | 01/28/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 | No dispute reported | 06/30/2026 | 792418567 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 01/27/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | No dispute reported | 06/30/2026 | 792413005 |
| Principal investigator 1 | Eli Lilly and Company | $25,232.00 | 01/26/2021 | Non-covered Recipient Entity NEWPORT HUNTINGTON MEDICAL GROUP | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 819461417 |
| Principal investigator 1 | Eli Lilly and Company | $442.65 | 01/26/2021 | Non-covered Recipient Entity VANCOUVER CLINIC INC PS | A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 819470173 |
| Principal investigator 1 | ABBVIE INC. | $2,895.52 | 01/25/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | No dispute reported | 06/30/2026 | 792412141 |
| Principal investigator 1 | ABBVIE INC. | $748.27 | 01/13/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 | No dispute reported | 06/30/2026 | 792408999 |
| Principal investigator 1 | Eli Lilly and Company | $5,174.00 | 01/12/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 819452617 |
| Principal investigator 1 | Eli Lilly and Company | $69,595.00 | 01/04/2021 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 IN PREVENTING SARS COV 2 INFECTION AND COVID 19 IN SKILLED NURSING AND ASSISTED LIVING FACILITY RESIDENTS AND STAFF A NIAID AND LILLY COLLABORATIVE STUDY | No dispute reported | 06/30/2026 | 819452357 |